secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2024-07-23T23:59:59+00:00
Accession:  0001493152-24-028818
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem licenses Phexxi to Pharma 1 for Middle East; closes $500K private placement with Aditxt
--------------------------------------------------------------------------------

- Exclusive 5-year license for Phexxi in UAE, Kuwait, Saudi Arabia, Qatar and other Middle East countries.
- Pharma 1 to file UAE regulatory submission in Q3 2024; UAE contraceptive market projected $185.1M by 2030.
- Pharma 1 pays cost-to-manufacture plus fee; must maintain at least 4 months of inventory at all times.
- Evofem closed $500K private placement with Aditxt via 500 shares of Series F-1 Preferred Stock.
- Merger with Aditxt targeting September 30, 2024 closing; amended merger agreement dated July 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224028818/0001493152-24-028818-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224028818/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-028818

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer